Trial
NCT05481775
Evaluating Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung Cancer
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Sun Yat-sen University
Collaborators
—
Condition
Locally Advanced Non-small Cell Lung Cancer
Intervention
Anlotinib
Why stopped
Clincal decision based on previous results
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-11-21